Biofrontera Inc. (NASDAQ:BFRI) Short Interest Update

Biofrontera Inc. (NASDAQ:BFRI) saw a significant drop in short interest during the month of August. As of August 14th, there was short interest totaling 32,907 shares, a drop of 46.1% from the July 30th total of 61,079 shares. Based on an average daily trading volume, of 464,283 shares, the short-interest ratio is currently 0.1 days. Currently, 0.2% of the shares of the company are short sold.

Hedge Funds Weigh In On Biofrontera

A hedge fund recently raised its stake in Biofrontera stock. Geode Capital Management LLC grew its stake in Biofrontera Inc. (NASDAQ:BFRI) by 54.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 65,677 shares of the company’s stock after purchasing an additional 23,074 shares during the period. Geode Capital Management LLC owned about 0.56% of Biofrontera worth $37,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 10.08% of the company’s stock.

Biofrontera Price Performance

NASDAQ:BFRI traded down $0.03 during trading hours on Tuesday, reaching $1.50. 208,272 shares of the company were exchanged, compared to its average volume of 381,323. The business has a 50 day moving average of $1.20 and a 200 day moving average of $1.03. Biofrontera has a 1-year low of $0.55 and a 1-year high of $1.61. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.18 and a quick ratio of 1.08. The company has a market capitalization of $22.35 million, a P/E ratio of -3.34 and a beta of 0.78.

Biofrontera (NASDAQ:BFRI) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.05. The company had revenue of $12.00 million for the quarter, compared to analysts’ expectations of $9.50 million. Biofrontera had a negative return on equity of 145.81% and a negative net margin of 13.78%. Research analysts forecast that Biofrontera will post -0.6 EPS for the current year.

Analyst Ratings Changes

A number of research firms have commented on BFRI. Wall Street Zen raised shares of Biofrontera to a “hold” rating in a research report on Saturday, July 18th. Zacks Research upgraded shares of Biofrontera from a “strong sell” rating to a “hold” rating in a research note on Monday, August 3rd. Finally, Weiss Ratings upgraded shares of Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold”.

About Biofrontera

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.